Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Compass Pathways PLC ADR CMPS
News
Compass Pathways Appoints Kelley Boucher as Chief People Officer
Compass Pathways to Participate in TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit on September 23, 2026
Compass Pathways Launches ‘Change the Tune in TRD’ in the U.S. to Advance HCP Understanding of Treatment-Resistant Depression at Psych Congress 2026
Fluence Selected by Compass Pathways to Develop Post-Approval COMP360 Provider Training
Compass Pathways Announces U.S. Grant Program Recipients for the Development of Post-Approval COMP360 Provider Training
Compass Pathways to Participate in Investor Conferences the Week of September 14th
Compass Pathways’ New 52-Week Topline Open-Label Data from Phase 3 COMP005 Trial Demonstrates Additional Benefit from Another COMP360 Dose in Part C Extending Durability Out to 1 Year
Compass Pathways to Debut U.S. HCP Education Campaign and Present New HEOR Data at Psych Congress 2026
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Compass Pathways Recognized as a 2026 Fierce 50 Breakthrough Honoree
Compass Pathways to Participate in 2026 Cantor Global Healthcare Conference on September 9, 2026
Compass Pathways to Participate in Canaccord Genuity's 46th Annual Growth Conference on August 12, 2026
Compass Pathways Working with U.S. Department of Veterans Affairs for Investigational Study of Psilocybin
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Compass Pathways Announces Second Quarter and First Half 2026 Financial Results and Business Highlights
Compass Pathways to Announce Second Quarter and First Half 2026 Financial Results on August 5, 2026
A Depression Drug Just Cleared a Key Hurdle Early, and the Market for New Mental Health Treatments Keeps Widening
Billions Flow Into Next-Generation Depression Treatments as Pharma Innovation Accelerates
Big Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real Time
United States